Global Multiplex Assays Market Set for Strong Growth as Precision Medicine and Advanced Diagnostics Accelerate

Global Multiplex Assays Market Overview

The Global Multiplex Assays Market is entering a strong growth phase as pharmaceutical companies, biotechnology firms, hospitals, and research laboratories increasingly adopt technologies capable of analyzing multiple biomarkers, nucleic acids, or cellular targets in a single test. According to Maximize Market Research, the market was valued at USD 4.21 billion in 2024 and is expected to reach approximately USD 8.20 billion by 2032, expanding at a CAGR of 8.7% from 2025 to 2032. Multiplex assays reduce sample requirements, testing time, reagent consumption, and laboratory workload compared with conducting multiple individual assays.

Rising chronic diseases, increasing demand for personalized medicine, expanding companion diagnostics, and growing pharmaceutical and biotechnology research are major factors supporting market growth. Multiplex technologies can simultaneously detect multiple disease markers, making them valuable in infectious-disease testing, cancer research, biomarker discovery, drug development, and genetic analysis. The growing elderly population and continued investment in life-science research are also widening the addressable market. At the same time, high acquisition and operating costs, technically complex workflows, and shortages of skilled personnel remain important challenges.

An important opportunity lies in the increasing use of protein multiplex assays for proteomics and biomarker research. Multiplexing allows researchers to analyze numerous potential biomarkers using comparatively small sample volumes while improving laboratory efficiency. As precision medicine moves toward increasingly individualized treatment decisions, the ability to obtain broad molecular information from a single sample is expected to become increasingly valuable.

* Explore the Latest Insights: https://www.maximizemarketresearch.com/request-sample/33651/

US Market Trends and Investment

The United States remains a major center for multiplex-assay development because of its large pharmaceutical and biotechnology ecosystem, advanced clinical infrastructure, and extensive research activity. In 2025, investment and portfolio activity continued to focus on higher-throughput molecular testing and advanced PCR technologies. Bio-Rad Laboratories, for example, expanded its digital PCR portfolio in July 2025 following its acquisition of Stilla Technologies and launched four new Droplet Digital PCR platforms. The expanded portfolio includes advanced multiplexing capabilities and more than 400,000 assays, strengthening applications in life-science research and diagnostics.

Thermo Fisher Scientific also made significant strategic moves in 2025, including its approximately $4.1 billion acquisition of Solventum's purification and filtration business, while separately exploring the potential sale of certain lower-growth diagnostics assets. The company also committed to increasing U.S. manufacturing investment, demonstrating the continued importance of domestic life-science infrastructure. These developments indicate that U.S. market growth is being shaped not only by assay innovation but also by consolidation, manufacturing investment, and portfolio optimization.

Market Segmentation

According to Maximize Market Research, the market is segmented by Product & Services, Type, Technology, Application, End User, and Region. By technology, Multiplex Real-Time PCR held the largest market share in 2024 and is expected to maintain its dominance during the forecast period, with a projected CAGR of 8.3%. Multiplex real-time PCR can amplify multiple target sequences within one reaction, allowing laboratories to identify several pathogens or genetic targets simultaneously. Its sensitivity, specificity, reduced sample requirements, faster testing, and lower reagent consumption support continued adoption across clinical diagnostics and research applications.

Multiplex Assays Market, Key Players are
1. Luminex Corporation (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. Illumina, Inc (United States)
4. Bio-Rad Laboratories, Inc. (United States)
5. Becton, Dickinson, and Company (United States)
6. Agilent Technologies, Inc. (United States)
7. Meso Scale Diagnostics (United States)
8. Quanterix (United States)
9. Bio-Techne Corporation (United States)
10. Promega Corporation (United States)
11. PerkinElmer, Inc. (United States)
12. Antigenix America, Inc. (United States)
13. Enzo Life Sciences, Inc. (United States)
14. Boster Biological Technology (United States)
15. Cayman Chemical Company (United States)
16. AYOXXA Biosystems GmbH |(Germany)
17. Merck KGaA (Germany)
18. Siemens Healthineers (Germany)
19. DiaSorin S.p.A. (Italy)
20. Olink (Sweden)
21. Qiagen N.V. (Netherlands)
22. Qiagen N.V. (Netherlands)
23. Abcam plc |(United Kingdom)
24. Abcam plc |(United Kingdom)
25. Randox Laboratories (United Kingdom)
26. Shimadzu Biotech (Japan)
27. Seegene (South Korea)

Competitive Analysis

Maximize Market Research identifies Luminex Corporation, Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories Inc., and Becton, Dickinson and Company, among others, as key participants in the global market. The supplied MMR report lists these companies but does not provide individual percentage shares, so an exact ranking of the five companies by global market share would require unsupported assumptions.

Luminex Corporation is a major multiplexing technology participant, with its platforms supporting high-throughput analysis of multiple biological targets. Its technology has contributed to the wider adoption of bead-based multiplex testing and biomarker analysis.

Thermo Fisher Scientific continues to strengthen its life-science and diagnostics portfolio through acquisitions, product development, and laboratory technology investment. Its 2025 acquisition activity demonstrates a strategy focused on expanding capabilities across the broader life-science workflow.

Illumina Inc. continues to support advanced genomic analysis, creating opportunities for multiplex approaches in molecular diagnostics, sequencing-related research, and precision medicine. Its broader technology ecosystem positions it to benefit from growing demand for multi-target biological analysis.

Bio-Rad Laboratories made one of the most significant 2025 technology moves by completing its acquisition of Stilla Technologies and expanding its Droplet Digital PCR portfolio. The new platforms combine high-precision quantification with advanced multiplexing capabilities, supporting research and diagnostic applications.

Becton, Dickinson and Company (BD) remains an important participant in molecular diagnostics and laboratory technologies. Its broad clinical diagnostics presence provides opportunities to integrate multiplex testing into increasingly automated diagnostic workflows.

Regional Analysis

United States: North America held approximately 42% of the global Multiplex Assays Market in 2024, making it the dominant regional market. Strong pharmaceutical and biotechnology research, chronic disease prevalence, product approvals, investments, and strategic initiatives by major companies are supporting regional leadership.

United Kingdom: The UK offers growth opportunities through its advanced healthcare system, biomedical research ecosystem, and emphasis on molecular diagnostics. Continued adoption of multiplex testing can support faster pathogen identification and more comprehensive clinical analysis.

Germany: Germany's established pharmaceutical and biotechnology industries, advanced research infrastructure, and demand for precision diagnostics create favorable conditions for multiplex assay adoption.

France: France's strong healthcare and life-science sectors provide opportunities for multiplex assays in clinical research, infectious-disease testing, and biomarker discovery.

Japan: Japan's advanced healthcare infrastructure, aging population, and sophisticated biotechnology sector can support demand for efficient diagnostic technologies capable of analyzing multiple targets from limited samples.

China: China represents a significant growth opportunity as healthcare infrastructure and biomedical research expand. Increasing demand for molecular diagnostics and investment by emerging biotechnology companies are expected to support multiplex assay adoption.

Conclusion

The Global Multiplex Assays Market is projected to increase from USD 4.21 billion in 2024 to USD 8.20 billion by 2032, reflecting an 8.7% CAGR from 2025 to 2032.

In my view, the most important growth opportunity will come from the convergence of multiplex real-time PCR, precision medicine, biomarker discovery, companion diagnostics, and high-throughput laboratory automation. The ability to analyze multiple targets from a single sample can reduce testing time and resource consumption while generating broader clinical and research information.

Future growth will increasingly depend on making multiplex platforms more affordable, automated, accurate, scalable, and user-friendly. Companies investing in advanced multiplexing, digital PCR, integrated workflows, and high-throughput diagnostic platforms are likely to benefit as healthcare systems and research organizations seek faster and more comprehensive molecular analysis.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 [email protected]